Kartos Therapeutics is a biotechnology firm pioneering small-molecule drugs targeting protein-protein interactions in oncology. Its lead candidate inhibits the CDK9 pathway to disrupt cancer cell growth. Primarily benefiting patients with hematologic malignancies, this precision therapy offers a novel treatment option for those with limited alternatives, advancing targeted cancer care.
Get alerts when this topic surges in newsletters. Free to start.
Sign up freeExplore more trends:Trending Topics ·AI Trends ·Business Trends ·Finance Trends ·Technology Trends